Can a new protein drug shield kids with cancer from dangerous infections?

NCT ID NCT07724756

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether a new drug called albipagrastim alfa can prevent severe neutropenia (dangerously low white blood cell counts) in children with sarcoma who are receiving chemotherapy. The drug is designed to stimulate the body's production of infection-fighting neutrophils. Researchers will measure how the drug behaves in the body, how well it protects against fever and infection, and whether it is safe for young patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a new drug called albipagrastim alfa (QLC2519) that stimulates white blood cell production
What this could lead to
If it works, this could offer a safer, more convenient way to prevent dangerous infections in children undergoing chemotherapy for sarcoma.
What could go wrong
This is a small, early-phase trial with only 18 participants, so results may not apply broadly. The drug could cause side effects or fail to prevent neutropenia as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FEBRILE NEUTROPENIA (FN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Children's Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.